Abstract
Drug-coated balloon (DCB) is a relatively novel device for coronary and peripheral artery disease management [1]. It consists in a conventional balloon angioplasty covered by an antiproliferative drug. This technology allows to bring high concentration of an antiproliferative drug with rapid local delivery without the implantation of an external prosthesis like a metal stent or a scaffold, technologies associated with some late-occurring thrombotic events. In this light, the shorter dual antiplatelet therapy (DAPT) duration usually required with DCB may be an advantage because it warrants a reduced bleeding risk, especially in high-risk and compromised patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cortese B, Granada JF, Scheller B, et al. Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. Eur Heart J. 2016;37:1096–103.
Cortese B, Berti S, Biondi-Zoccai G, et al. Drug-coated balloon treatment of coronary artery disease: a position paper of the Italian Society of Interventional Cardiology. Catheter Cardiovasc Interv. 2014;83:427–35.
Cortese B, Bertoletti A. Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. Int J Cardiol. 2012;161:4–12.
Kaule S, Minrath I, Stein F, et al. Correlating coating characteristics with the performance of drug-coated balloons – a comparative in vitro investigation of own established hydrogel- and ionic liquid-based coating matrices. PLoS One. 2015;10:e0116080.
Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S, Limbruno U. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart. 2010;96:1291–6.
Kufner S, Joner M, Schneider S, Tölg R, Zrenner B, Repp J, Starkmann A, Xhepa E, Ibrahim T, Cassese S, Fusaro M, Ott I, Hengstenberg C, Schunkert H, Abdel-Wahab M, Laugwitz KL, Kastrati A, Byrne RA, ISAR-DESIRE 4 Investigators. Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents: a randomized controlled trial. JACC Cardiovasc Interv. 2017;10:1332–40.
Kleber FX, Mathey DG, Rittger H, Scheller B, German Drug-eluting Balloon Consensus Group. How to use the drug-eluting balloon: recommendations by the German consensus group. EuroIntervention. 2011;7(Suppl K):K125–8.
Unverdorben M, Kleber FX, Heuer H, Figulla HR, Vallbracht C, Leschke M, Cremers B, Hardt S, Buerke M, Ackermann H, Boxberger M, Degenhardt R, Scheller B. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2010;99:165–74.
Mitomo S, Mangieri A, Regazzoli D, Ancona M, Giannini F, Chieffo A, Montorfano M, Latib A, Colombo A. TCT-526 mid-term clinical outcomes after bailout stenting with drug-eluting stent for suboptimal results of drug-coated balloon; Milan registry. J Am Coll Cardiol. 2017;70(18 Supplement):B218. https://doi.org/10.1016/j.jacc.2017.09.697.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Buccheri, D., Cortese, B. (2019). Previous Mistakes with DCB Technology, and How to Prevent Them in the Future. In: Cortese, B. (eds) Drug-Coated Balloons . Springer, Cham. https://doi.org/10.1007/978-3-319-92600-1_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-92600-1_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92599-8
Online ISBN: 978-3-319-92600-1
eBook Packages: MedicineMedicine (R0)